Vyripharm Cannabis Testing Platform Issued Patent

Vyripharm
Vyripharm Biopharmaceuticals Issued Patent for Comprehensive Medical Cannabis Testing from Agriculture to Clinical Applications

Raising the Bar for Comprehensive Medical Cannabis and Hemp Testing and Evaluation

HOUSTON, March 17, 2017 /PRNewswire/ — Vyripharm Biopharmaceuticals, a privately held biopharmaceutical company located in the Texas Medical Center in Houston, Texas is pleased to announce that it has been granted patent allowance by the United States Patent and Trade Office for its comprehensive medical cannabis and hemp testing methodology platform [“Integrated Systems and Methods of Evaluating Cannabis and Cannabinoid Products for Public Safety, Quality Control and Quality Assurance Purposes” Patent# US20150219610 A1]. The medical cannabis and hemp markets, which continues to expand on a state by state basis throughout the U.S., is in serious need of a comprehensive analytical approach to assure public safety in respect to medical cannabinoids/medical cannabinoid products.

The expandable testing platform is designed to perform a wide range of QA/QC services from agriculture to clinical applications including cannabinoid profiling, microbial and genomic analysis (other omics analysis), purity, identification of any existing pathogens, identification of any existing additives and other data as needed. This will help facilitate compliance with state and federal regulations and protect them from issues surrounding the “Grey Market”. Vyripharm believes that the future success of medical cannabis and hemp based products will be dependent on a strong and secure QA/QC program nationwide to protect the public interest and goodwill.

We are standing on the cusp of a precision medicine revolution. Our analytical testing methodology platform coupled with our precision medicine technology allows us to evaluate medicinal cannabinoids on a pharmaceutical grade level. This should help accelerate cannabinoid based drug development, foster novel IP expansion and improve patients’ quality of life.

elias-jackson-vyripharmDr. Elias Jackson, Director of Scientific Relations for Vyripharm

ABOUT VYRIPHARM BIOPHARMACEUTICALS

Vyripharm is a biopharmaceutical firm focused on botanicals (medical cannabinoids products, such as medical cannabis and hemp) regulatory testing, pharmaceutical drug development, Bioinformatics, Medical Informatics, monitoring technology, development of imaging agents, and drug delivery systems. The aim of Vyripharm is to improve clinical management through diagnosis and treatment with botanicals, synthetic pharmaceuticals, and drug delivery systems. For more information visit www.vyripharmbio.com

Original press release: http://www.prnewswire.com/news-releases/vyripharm-biopharmaceuticals-issued-patent-for-comprehensive-medical-cannabis-testing-from-agriculture-to-clinical-applications-300425314.html

Published by NCV Newswire

The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. For questions contact us.


Latest News
Get The App

Download the free “New Cannabis Ventures” app on the iOS App Store or Google Play and get real-time push notifications straight to your phone on the latest breaking news and exclusives published.


ncv-news-ios-app-store

ncv-news-google-play

NCV Media, LLC

Thank you for reading

New Cannabis Ventures

Contributing original content and curating quality news on only the most promising cannabis companies and the most influential investors.

FOLLOW US ON